Sun Formally Denies Insider Trading Before Ranbaxy Purchase Announced
This article was originally published in PharmAsia News
Executive Summary
Sun Pharmaceutical Industries issued a formal denial of accusations it was guilty of insider trading before it announced an intent to buy Ranbaxy Laboratories for $3.2 billion.